SG11202102765RA - Humanised anti-n-truncated amyloid beta monoclonal antibody - Google Patents
Humanised anti-n-truncated amyloid beta monoclonal antibodyInfo
- Publication number
- SG11202102765RA SG11202102765RA SG11202102765RA SG11202102765RA SG11202102765RA SG 11202102765R A SG11202102765R A SG 11202102765RA SG 11202102765R A SG11202102765R A SG 11202102765RA SG 11202102765R A SG11202102765R A SG 11202102765RA SG 11202102765R A SG11202102765R A SG 11202102765RA
- Authority
- SG
- Singapore
- Prior art keywords
- monoclonal antibody
- amyloid beta
- humanised anti
- truncated amyloid
- beta monoclonal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201816210 | 2018-10-04 | ||
| PCT/EP2019/076772 WO2020070225A1 (en) | 2018-10-04 | 2019-10-02 | Humanised anti-n-truncated amyloid beta monoclonal antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202102765RA true SG11202102765RA (en) | 2021-04-29 |
Family
ID=68136417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202102765RA SG11202102765RA (en) | 2018-10-04 | 2019-10-02 | Humanised anti-n-truncated amyloid beta monoclonal antibody |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12297261B2 (enExample) |
| EP (1) | EP3861023A1 (enExample) |
| JP (1) | JP7610515B2 (enExample) |
| KR (1) | KR102862077B1 (enExample) |
| CN (1) | CN113056480B (enExample) |
| BR (1) | BR112021006153A2 (enExample) |
| EA (1) | EA202190954A1 (enExample) |
| IL (1) | IL281979B2 (enExample) |
| MX (1) | MX2021003867A (enExample) |
| SG (1) | SG11202102765RA (enExample) |
| WO (1) | WO2020070225A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3658172A4 (en) | 2017-07-25 | 2021-05-05 | TrueBinding, Inc. | TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND |
| CN113711036B (zh) | 2019-01-30 | 2025-03-18 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| US20230151069A1 (en) | 2020-03-10 | 2023-05-18 | Lifearc | Cyclic Peptides |
| CN116157151A (zh) | 2020-05-26 | 2023-05-23 | 真和制药有限公司 | 通过阻断半乳凝素-3治疗炎性疾病的方法 |
| EP4638494A1 (en) | 2022-12-22 | 2025-10-29 | BioArctic AB | Antibody which binds to abetape3 |
| TW202607032A (zh) | 2024-06-20 | 2026-02-16 | 瑞典商生物極公司 | 雙特異性結合分子 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US474900A (en) | 1892-05-17 | William byrnes | ||
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| PT2099826E (pt) | 2007-01-05 | 2014-01-09 | Univ Zuerich | Anticorpo anti-beta-amilóide e suas utilizações |
| CA2703825A1 (en) | 2007-10-29 | 2009-05-07 | Innogenetics Nv | New antibodies specific of the .beta.-amyloid peptides and their uses as diagnostic agents or drugs |
| US8795664B2 (en) | 2010-06-04 | 2014-08-05 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Monoclonal antibodies targeting amyloid beta oligomers |
| DK3269736T3 (da) * | 2012-05-10 | 2020-01-13 | Georg August Univ Goettingen Stiftung Oeffentlichen Rechts Univsmedizin | Konformationsspecifikke antistoffer mod oligomerer af amyloid beta |
| WO2015173133A1 (en) * | 2014-05-12 | 2015-11-19 | Chiesi Farmaceutici S.P.A. | Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy |
| CA2992386A1 (en) | 2015-07-16 | 2017-01-19 | Probiodrug Ag | Humanized antibodies |
| CN111518206B (zh) * | 2019-02-01 | 2022-03-29 | 长春金赛药业有限责任公司 | 人源化抗Aβ单克隆抗体及其应用 |
| US20230151069A1 (en) * | 2020-03-10 | 2023-05-18 | Lifearc | Cyclic Peptides |
-
2019
- 2019-10-02 IL IL281979A patent/IL281979B2/en unknown
- 2019-10-02 JP JP2021543565A patent/JP7610515B2/ja active Active
- 2019-10-02 US US17/282,592 patent/US12297261B2/en active Active
- 2019-10-02 EA EA202190954A patent/EA202190954A1/ru unknown
- 2019-10-02 CN CN201980065883.5A patent/CN113056480B/zh active Active
- 2019-10-02 WO PCT/EP2019/076772 patent/WO2020070225A1/en not_active Ceased
- 2019-10-02 KR KR1020217012796A patent/KR102862077B1/ko active Active
- 2019-10-02 BR BR112021006153-3A patent/BR112021006153A2/pt unknown
- 2019-10-02 EP EP19782593.8A patent/EP3861023A1/en active Pending
- 2019-10-02 SG SG11202102765RA patent/SG11202102765RA/en unknown
- 2019-10-02 MX MX2021003867A patent/MX2021003867A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210080400A (ko) | 2021-06-30 |
| AU2019354714A1 (en) | 2021-04-29 |
| JP7610515B2 (ja) | 2025-01-08 |
| EP3861023A1 (en) | 2021-08-11 |
| US12297261B2 (en) | 2025-05-13 |
| MX2021003867A (es) | 2021-09-08 |
| US20210347867A1 (en) | 2021-11-11 |
| JP2022513331A (ja) | 2022-02-07 |
| CA3114669A1 (en) | 2020-04-09 |
| IL281979A (en) | 2021-05-31 |
| WO2020070225A1 (en) | 2020-04-09 |
| EA202190954A1 (ru) | 2021-06-29 |
| IL281979B2 (en) | 2025-09-01 |
| US20230203140A9 (en) | 2023-06-29 |
| IL281979B1 (en) | 2025-05-01 |
| BR112021006153A2 (pt) | 2021-06-29 |
| KR102862077B1 (ko) | 2025-09-18 |
| CN113056480A (zh) | 2021-06-29 |
| CN113056480B (zh) | 2025-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283812A (en) | Humanized antibody against human pd–1 | |
| IL281979A (en) | Human antibodies that bind amyloid peptides | |
| IL279235A (en) | DLL3-CD3 bispecific antibodies | |
| IL269003A (en) | Anti-n3pglu amyloid beta peptide antibodies and uses thereof | |
| SG11202102882YA (en) | Antigen-binding molecule comprising altered antibody variable region | |
| IL282756A (en) | Humanized antibodies against SIRPα | |
| ZA202104357B (en) | Monoclonal antibodies against the beta chain region of human trbv9 | |
| ZA202004908B (en) | Bispecific antibody | |
| ZA201800048B (en) | Anti-pyroglutamated amyloid beta humanized antibodies | |
| ZA202101537B (en) | Anti-trem-2 agonist antibodies | |
| IL263936A (en) | Humanized monoclonal antibodies targeting hptp-beta)ve-ptp) | |
| ZA202205226B (en) | Ri-labeled humanized antibody | |
| IL280757A (en) | Monoclonal antibodies against human tim-3 | |
| EP3802622A4 (en) | NEW BISPECIFIC ANTI-CD3 / ANTI-CD20 ANTIBODY | |
| SG11202100607RA (en) | Humanized antibodies against psma | |
| IL282355A (en) | Bispecific antibodies directed to exosomes | |
| IL286918A (en) | Bispecific antibody | |
| EP3825334A4 (en) | HUMANIZED MONOCLONAL ANTI-HER3 ANTIBODY | |
| EP4001306A4 (en) | Humanized anti-vegf monoclonal antibody | |
| IL290050A (en) | Bispecific antibody | |
| ZA202102874B (en) | Monoclonal antibody that specifically binds to cd20 | |
| GB201820006D0 (en) | Humanised anti-IL17BR antibody | |
| GB201911211D0 (en) | Monoclonal antibodies against ambra-1 | |
| EP3955925C0 (en) | Humanized Anti-PD-L1 Antibodies | |
| GB201911213D0 (en) | Monoclonal antibodies against loricrin |